Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Salgia

Showing results (31-40 of 528) with videos related to

Pageof 53
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
MET as a possible target for non-small-cell lung cancerAhad A Sadiq, Ravi Salgia
Expert Opinion on Investigational Drugs|March 25, 2014
Mitochondrial dynamics: biology and therapy in lung cancerFrances E Lennon, Ravi Salgia
Respirology (Carlton, Vic.)|October 21, 2006
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancerSyed M Ahmed, Ravi Salgia
Cell Adhesion & Migration|February 9, 2010
MET molecular mechanisms and therapies in lung cancerRyan E Lawrence, Ravi Salgia
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2012
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factorAhad A Sadiq, Ravi Salgia
Journal of Carcinogenesis|April 20, 2013
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?Victoria M Villaflor, Ravi Salgia
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 1, 2009
MET pathway as a therapeutic targetEric S Kim, Ravi Salgia
Journal of the National Comprehensive Cancer Network : JNCCN|September 26, 2009
Novel targets for therapeutic agents in small cell lung cancerPatrick C Ma, Ravi Salgia
American Journal of Clinical Oncology|August 13, 2013
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung CancerRobert M Sargis, Ravi Salgia
Clinical Lung Cancer|November 12, 2003
p53 and Bcl-2 in small cell-lung cancerRavi Salgia, Arthur T Skaring
Pageof 53

Showing results (31-40 of 528) with videos related to

Sort By:
Pageof 53
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
MET as a possible target for non-small-cell lung cancerAhad A Sadiq, Ravi Salgia
Expert Opinion on Investigational Drugs|March 25, 2014
Mitochondrial dynamics: biology and therapy in lung cancerFrances E Lennon, Ravi Salgia
Respirology (Carlton, Vic.)|October 21, 2006
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancerSyed M Ahmed, Ravi Salgia
Cell Adhesion & Migration|February 9, 2010
MET molecular mechanisms and therapies in lung cancerRyan E Lawrence, Ravi Salgia
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2012
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factorAhad A Sadiq, Ravi Salgia
Journal of Carcinogenesis|April 20, 2013
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?Victoria M Villaflor, Ravi Salgia
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 1, 2009
MET pathway as a therapeutic targetEric S Kim, Ravi Salgia
Journal of the National Comprehensive Cancer Network : JNCCN|September 26, 2009
Novel targets for therapeutic agents in small cell lung cancerPatrick C Ma, Ravi Salgia
American Journal of Clinical Oncology|August 13, 2013
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung CancerRobert M Sargis, Ravi Salgia
Clinical Lung Cancer|November 12, 2003
p53 and Bcl-2 in small cell-lung cancerRavi Salgia, Arthur T Skaring
Pageof 53